Abstract
Most data regarding survival in patients with chondrosarcoma are limited to case studies and small series performed at single institutions. A systematic review was performed to study the relationship between potential prognostic factors and survival. The survival rates were analyzed according to modality of treatment, treatment history, histological subtype, and histological grade. A total of 560 patients with intracranial chondrosarcoma were analyzed. Median follow-up time was 60 months. The 5-year mortality among all patients was 11.5% with median survival of 24 months. Mortality at 5 years was significantly greater for patients with tumors of higher grade, or of the mesenchymal subtype, or who had received surgical resection alone. The results of our systematic review provide useful data in predicting survival among intracranial chondrosarcoma patients.
Original language | English (US) |
---|---|
Pages (from-to) | 1547-1551 |
Number of pages | 5 |
Journal | Journal of Clinical Neuroscience |
Volume | 16 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2009 |
Funding
The authors gratefully acknowledge the following sources of support: IY was partially supported by a UCSF Clinical and Translational Scientist Training Research Award and a NIH National Research Service Award grant. SJH was funded by a Howard Hughes Medical Institute Research Training Fellowship. ATP the senior author is partially funded by a Reza and Georgianna Khatib Endowed Chair in Skull Base Tumor Surgery.
Keywords
- Cranial chondrosarcoma
- Survival outcomes
- Systematic review
ASJC Scopus subject areas
- Clinical Neurology
- Neurology
- Physiology (medical)
- Surgery